Competitive Technologies (CTT) made a new 52-week high at $3.57 yesterday (May 13) on 5X average daily trading volume before doing an understandable retracement, which is continuing today at $2.90.
Why the recent price appreciation coupled with increased liquidity? For one, there is much anticipation for the first comprehensive presentation of CTT's chronic pain management therapy device (named "Calmare"--Italian for "calm, soothe, pacify") to the medical community to be held this Monday, May 17. The inventor of Calmare, Professor Giuseppe Marineo, MD, DSc., Researcher, Founding President of Delta Research and Development, Tor Vergata University of Rome, Italy, is the keynote speaker at the Symposium for physicians. Dr. Marineo will present his "Scrambler Therapy," which interferes with pain signal transmission by ''mixing'' ''non-pain'' information into the nerve fibres. Other speakers include physicians from the Boston Foundation for Sight, the University of Miami, the University of Wisconsin, and Calmar Pain Relief, LLC, to present evidence-based patient case studies developed from the use of the Calmare system to treat various types of chronic pain from cancer and chemotherapy-induced peripheral neuropathy (CIPN), failed back surgery, phantom limb syndrome, sciatica, pain from shingles etc.. These case studies involved patients suffering from intractable pain after trying to get relief from other pain management treatments, such as painkillers. Patients that cannot use painkillers due to negative side effects were also included.
And just three weeks later, Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, will be presenting a study evaluating the treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTT's Calmare Pain Therapy Treatment at the American Society of Clinical Oncology's (ASCO) Annual Meeting on June 8, 2010. Anyone who has followed biotech and medical device technology stocks are aware that ASCO is one of the most attended medical conferences--atteneded by the medical community AND investment research analysts, investors and medical and financial media. Dr. Smith's article on this study has been accepted (after a peer review) for publication in a highly respected medical journal.
The market for a non-narcotic and non-invasive treatment for pain cannot be understated--it is a huge market. In a Wall Street Journal article in the May 11 edition entitled, New Ways to Treat Pain, it was noted that about "76.5 million Americans, or about 26% of all adults, suffer from chronic pain, generally defined as any pain that lasts more than six months. Medical experts say the condition can be as debilitating as many severe diseases, leaving the patient exhausted and unable to carry on with many everyday activities." According to the American Pain Foundation, more Americans suffer from chronic pain than from cancer, diabetes and heart disease and cancer--- combined-- costing about $100 Billion annually as measured in direct treatment costs, lost income and reduced productivity. With the relatively modest costs associated with treatment by CTT's Calmare technology and the obvious concern with rising healthcare costs, economical and effective treatments could see approval for Medicare reimbursement sooner rather than later as more Calmare units are placed throughout the country and more data is evaluated. Meanwhile, "early adopters" are placing orders with CTT for pain managment clinics and medical practices through CTT's distribution network that is expanding.
On a timely note, CTT will be announcing its Third Quarter results in the next few days which will reflect revenue from at least 40 units shipped to CTT's Switzerland-based distributor, Life Episteme Group (NYSE:LPG). Another 60 units have already been ordered by LPG and should hit CTT's revenue line in the current quarter. With all the new attention to CTT's cost efficient and medically effective technology, the proverbial "hockey stick" chart in sales may be forthcoming in future quarters. With only 11 Million shares outstanding, CTT has a current market cap of $31.9 Million (at $2.90)---a market cap which may be deemed incredibly low as CTT's medical evidence is released.
(As an aside to traders, with such a low share count and a public float of less than 10 million shares, the stock can be volatile. But volatility is the traders' friend).
Disclosure: Long CTT